Skip to main content
. Author manuscript; available in PMC: 2012 Aug 10.
Published in final edited form as: Breast Cancer Res Treat. 2012 Jan 3;134(1):101–115. doi: 10.1007/s10549-011-1925-0

Fig. 1.

Fig. 1

SLC22A5 expression in breast cancer. a SLC22A5 expression in breast cancer cell lines as determined by qRT-PCR. b SLC22A5 expression in ER-positive and ER-negative cell lines. Left panel qRT-PCR data of this study; right panel cDNA microarray dataset [48]. c SLC22A5 expression in breast tumor tissue specimens from 15 studies including a total of more than 2,000 patients. Studies 1–15 are from the clinical microarray datasets [33–47]. d The correlation between SLC22A5 and ER expression in breast tumor tissue specimens. Shown is the correlation data from the largest dataset, comprised of 295 patients [42]. Analyses of other datasets also generated similar results (data not shown)